Harrow reports Q1 EPS (28c), consensus (20c)

Reports Q1 revenue $34.6M, consensus $37.3M. “Our primary focus for 2024 remains on three key operational initiatives – building a formidable dry eye disease franchise, including successfully launching VEVYE(R); continuing to build a retina franchise with IHEEZO(R) and TRIESENCE(R); and stabilizing ImprimisRx and our Anterior Segment Products and returning them to a growth trajectory,” said Mark L. Baum, CEO. “I am very pleased with the success we had in all three of these areas during the first quarter, and I remain optimistic for 2024 based on what we are seeing in the second quarter. Given the strength we see with both IHEEZO and VEVYE, the upcoming re-introduction of TRIESENCE to the ophthalmic market, and the significant momentum that we have built so far in 2024, we are well positioned to meet our 2024 revenue guidance of more than $180 million.”